Arca Biopharma (NASDAQ:ABIO) and Celldex Therapeutics (NASDAQ:CLDX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, analyst recommendations, profitability, dividends and risk.
This is a summary of current recommendations and price targets for Arca Biopharma and Celldex Therapeutics, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Arca Biopharma currently has a consensus target price of $2.00, suggesting a potential upside of 440.39%. Celldex Therapeutics has a consensus target price of $40.00, suggesting a potential upside of 10,106.69%. Given Celldex Therapeutics’ higher possible upside, analysts clearly believe Celldex Therapeutics is more favorable than Arca Biopharma.
Valuation & Earnings
This table compares Arca Biopharma and Celldex Therapeutics’ gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Arca Biopharma||N/A||N/A||-$18.49 million||N/A||N/A|
|Celldex Therapeutics||$12.74 million||5.31||-$93.03 million||($0.80)||-0.49|
Arca Biopharma has higher earnings, but lower revenue than Celldex Therapeutics.
Risk and Volatility
Arca Biopharma has a beta of 1.98, meaning that its stock price is 98% more volatile than the S&P 500. Comparatively, Celldex Therapeutics has a beta of 4.47, meaning that its stock price is 347% more volatile than the S&P 500.
This table compares Arca Biopharma and Celldex Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Institutional and Insider Ownership
13.8% of Arca Biopharma shares are held by institutional investors. Comparatively, 27.8% of Celldex Therapeutics shares are held by institutional investors. 3.6% of Arca Biopharma shares are held by company insiders. Comparatively, 2.9% of Celldex Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Celldex Therapeutics beats Arca Biopharma on 7 of the 11 factors compared between the two stocks.
Arca Biopharma Company Profile
ARCA biopharma, Inc., a biopharmaceutical company, focuses on developing genetically-targeted therapies for cardiovascular diseases. The company's lead product candidate is Gencaro, a pharmacologically beta-blocker and mild vasodilator, which is in clinical trial for the treatment of atrial fibrillation in chronic heart failure patients with reduced left ventricular ejection fraction. It also engages in the development of a preclinical plan for AB171, a new chemical entity for the treatment of various cardiovascular indications, such as peripheral arterial disease and chronic heart failure. The company has a collaboration agreement with Medtronic, Inc. for the support of GENETIC-AF Phase 2B clinical trials; and Laboratory Corporation of America to provide the companion diagnostic test and services to support GENETIC-AF trial. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.
Celldex Therapeutics Company Profile
Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of various immunotherapy technologies and other cancer-targeting biologics. Its drug candidates include glembatumumab vedotin, an antibody-drug that is in Phase IIb study for the treatment of triple negative breast cancer and a Phase II study for the treatment of metastatic melanoma; Varlilumab, an immune modulating antibody that is in a Phase 1 study designed to enhance a patient's immune response against cancer; and CDX-3379, a human monoclonal antibody that is in Phase II study in combination with cetuximab for the treatment of head and neck squamous cell carcinoma. The company also develops earlier stage drug candidates that are in clinical development, including CDX-014, an antibody-drug conjugate targeting renal and ovarian cancers; CDX-1140, a human monoclonal antibody; CDX-301, an immune cell mobilizing agent and dendritic cell growth factor; and CDX-1401, an immunotherapeutic aimed at antigen presenting cells for cancer indications. Celldex Therapeutics, Inc. has research collaboration and license agreements with Medarex, Inc.; Rockefeller University; University of Southampton; Amgen Inc.; Amgen Fremont; Seattle Genetics, Inc.; Yale University; and MedImmune, LLC. The company is headquartered in Hampton, New Jersey.
Receive News & Ratings for Arca Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arca Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.